Results 171 to 180 of about 1,434,677 (298)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Phenotyping vasodilator responsiveness in idiopathic pulmonary arterial hypertension: any role for the cardiopulmonary exercise test?

open access: yesERJ Open Research
Gayathiri Sivasubramaniam   +6 more
doaj   +1 more source

The Swiss registry for pulmonary arterial hypertension: the paediatric experience.

open access: yes, 2007
Pulmonary arterial hypertension is a rare disease with a poor prognosis. Epidemiological data are scarce, particularly in the paediatric population. A registry was recently developed in order to collect epidemiological data on patients with pulmonary ...
Tolsa, J.F.   +2 more
core  

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken   +7 more
wiley   +1 more source

Haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension

open access: yesERJ Open Research
Alejandro Cruz-Utrilla   +12 more
doaj   +1 more source

Update on pulmonary hypertension complicating chronic obstructive pulmonary disease

open access: yes, 2009
Soma Jyothula, Zeenat SafdarPulmonary-Critical Care Medicine, Baylor College of Medicine, Houston, TX, USAAbstract: Pulmonary hypertension (PH) is the hemodynamic manifestation of various pathological processes that result in elevated pulmonary artery ...
Zeenat Safdar, Soma Jyothula
core  

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy